The ISPY COVID Investigators would like to respond to Dal-Re et al. in their recent editorial in on the ethics of the consent process in the ISPY
COVID Trial [
[1]
]. Unfortunately, the authors of the editorial have fundamentally misunderstood the
consent process, which is not described accurately in their editorial.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Internal MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Participants' informed consent in adaptive, platform drug trials in hospitalized COVID-19 patients: not all approaches are ethically acceptable.Eur J Intern Med. 2022; 103: 1-3
- I-SPY COVID adaptive platform trial for COVID-19 acute respiratory failure: rationale, design and operations.BMJ Open. 2022; 12e060664
- Assessment of length and readability of informed consent documents for COVID-19 vaccine trials.JAMA Netw Open. 2021; 4e2110843
Article Info
Publication History
Published online: September 30, 2022
Accepted:
September 21,
2022
Received in revised form:
September 19,
2022
Received:
September 2,
2022
Publication stage
In Press Corrected ProofIdentification
Copyright
© 2022 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
